Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 360° synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of hemophilia across the globe
3.2.1.2 Rise in favorable government initiatives
3.2.1.3 Increase in R&D and new product development
3.2.1.4 Growing adoption of prophylaxis treatment
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost associated with hemophilia treatment
3.2.2.2 Lack of awareness in developing and under-developed regions
3.2.2.3 Low adoption rates of technologically advanced products
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Hemophilia A
5.2.1 Severe
5.2.2 Moderate
5.2.3 Mild
5.3 Hemophilia B
5.3.1 Severe
5.3.2 Moderate
5.3.3 Mild
5.4 Other disease types
Chapter 6 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Recombinant coagulation factor concentrates
6.2.1 Factor VIII
6.2.2 Factor IX
6.3 Plasma-derived coagulation factor concentrates
6.3.1 Factor VIII
6.3.2 Factor IX
6.4 Extended half-life products
6.4.1 Factor VIII
6.4.2 Factor IX
6.5 Desmopressin
6.6 Antifibrinolytic agents
6.7 Gene therapy products
Chapter 7 Market Estimates and Forecast, By Patient, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Pediatric
- 7.2.1. 0to 4
- 7.2.2. 5to 13
- 7.2.3. 14to18
7.3 Adult
- 7.3.1. 19to 44
- .7.3.2. 45+
Chapter 8 Market Estimates and Forecast, By Treatment, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Prophylaxis
8.3 On demand
Chapter 9 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 Factor replacement therapy
9.3 Non-factor replacement therapy
Chapter 10 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
10.1 Key trends
10.2 Vasopressin
10.3 Coagulation factors
Chapter 11 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
11.1 Key trends
11.2 Injectable
11.3 Nasal spray
11.4 Oral
Chapter 12 Market Estimates and Forecast, By End-use, 2021 – 2032 ($ Mn)
12.1 Key trends
12.2 Hospitals
12.3 Clinics
12.4 Hemophilia treatment centers
12.5 Other end-users
Chapter 13 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
13.1 Key trends
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.3 Europe
13.3.1 Germany
13.3.2 UK
13.3.3 France
13.3.4 Spain
13.3.5 Italy
13.3.6 Netherlands
13.3.7 Rest of Europe
13.4 Asia Pacific
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Rest of Asia Pacific
13.5 Latin America
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest of Latin America
13.6 Middle East and Africa
13.6.1 South Africa
13.6.2 Saudi Arabia
13.6.3 UAE
13.6.4 Rest of Middle East and Africa
Chapter 14 Company Profiles
14.1 Bayer AG
14.2 Biogen Inc.
14.3 Biotest AG (Grifols, S.A.)
14.4 BioMarin Pharmaceutical Inc
14.5 CSL Behring LLC
14.6 Ferring B.V.
14.7 Genentech, Inc. (Roche Holding AG)
14.8 Kedrion S.p.A
14.9 Novo Nordisk A/S
14.10 Octapharma AG
14.11 Pfizer, Inc.
14.12 Sanofi SA
14.13 Swedish Orphan Biovitrum AB
14.14 Takeda Pharmaceutical Company Limited
